Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C60 |
| Molecular Weight | 720.642 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
c12c3c4c5c1c6c7c8c2c9c%10c3c%11c%12c4c%13c%14c5c%15c6c%16c7c%17c%18c8c9c%19c%20c%10c%11c%21c%22c%12c%13c%23c%24c%14c%15c%25c%16c%26c%17c%27c%18c%19c%28c%20c%21c%29c%22c%23c%30c%24c%25c%26c%31c%27c%28c%29c%30%31
InChI
InChIKey=XMWRBQBLMFGWIX-UHFFFAOYSA-N
InChI=1S/C60/c1-2-5-6-3(1)8-12-10-4(1)9-11-7(2)17-21-13(5)23-24-14(6)22-18(8)28-20(12)30-26-16(10)15(9)25-29-19(11)27(17)37-41-31(21)33(23)43-44-34(24)32(22)42-38(28)48-40(30)46-36(26)35(25)45-39(29)47(37)55-49(41)51(43)57-52(44)50(42)56(48)59-54(46)53(45)58(55)60(57)59
| Molecular Formula | C60H2 |
| Molecular Weight | 722.6579 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Association of Hg2+ with aqueous (C60)n aggregates facilitates increased bioavailability of Hg2+ in Zebrafish (Danio rerio). | 2013-09-03 |
|
| Distinct immunomodulatory effects of a panel of nanomaterials in human dermal fibroblasts. | 2012-05-05 |
|
| Photodynamic anticancer activities of water-soluble C(60) derivatives and their biological consequences in a HeLa cell line. | 2012-01-05 |
|
| Protective effects of nanostructures of hydrated C(60) fullerene on reproductive function in streptozotocin-diabetic male rats. | 2011-04-11 |
|
| Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro. | 2011-02 |
|
| Carbon fullerenes (C60s) can induce inflammatory responses in the lung of mice. | 2010-04-15 |
|
| Fullerene derivatives induce premature senescence: a new toxicity paradigm or novel biomedical applications. | 2010-04-15 |
|
| Identification of potential biomarkers from gene expression profiles in rat lungs intratracheally instilled with C(60) fullerenes. | 2010-04-14 |
|
| The co-application effects of fullerene and ascorbic acid on UV-B irradiated mouse skin. | 2010-01-12 |
|
| Attenuation of delayed-type hypersensitivity by fullerene treatment. | 2009-06-30 |
|
| Oxidatively damaged DNA in rats exposed by oral gavage to C60 fullerenes and single-walled carbon nanotubes. | 2009-05 |
|
| Gene expression profiles in rat lung after inhalation exposure to C60 fullerene particles. | 2009-04-05 |
|
| Impact of physicochemical properties of engineered fullerenes on key biological responses. | 2009-01-01 |
|
| Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome. | 2007-12 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:50:38 GMT 2025
by
admin
on
Mon Mar 31 20:50:38 GMT 2025
|
| Record UNII |
NP9U26B839
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C62379
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
33416
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
DTXSID4031772
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
BUCKMINSTERFULLERENE
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
123591
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
99685-96-8
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
33128
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
D037741
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
C62380
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | NCIT | ||
|
C069837
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
NP9U26B839
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | |||
|
m2742
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
1435890
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY | RxNorm | ||
|
NP9U26B839
Created by
admin on Mon Mar 31 20:50:38 GMT 2025 , Edited by admin on Mon Mar 31 20:50:38 GMT 2025
|
PRIMARY |